Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials

BACKGROUND: Tanezumab is a nerve growth factor monoclonal antibody that may regulate pain in hip or knee osteoarthritis (OA). This meta-analysis was performed to evaluate the efficacy and safety of low and moderate doses of tanezumab in treating hip or knee OA. METHODS: PubMed, EMBASE, the Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Di, Luo, Ming-hui, Pan, Jian-ke, Zeng, Ling-feng, Liang, Gui-hong, Han, Yan-hong, Liu, Jun, Yang, Wei-yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Addressing the Challenges Associated With the Development, Testing and Approval of Novel Therapeutics for Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777347/
https://www.ncbi.nlm.nih.gov/pubmed/35069811
http://dx.doi.org/10.1177/1759720X211067639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777347/
https://www.ncbi.nlm.nih.gov/pubmed/35069811
http://dx.doi.org/10.1177/1759720X211067639

Ejemplares similares